Teva receives approval for generic Eloxatin
Teva Pharmaceutical Industries Ltd began selling a generic injectable version of Eloxatin, a chemotherapy drug, after the approval of the FDA. The oxaliplatin drug is available in 50 mg and 100 mg dosage. The US sales of Eloxatin totaled $1.3 billion in 2008 and the drug is approved to treat advanced colon cancer and stage III colon cancer following surgery.
- Sun Pharma gets tentative FDA nod for generic Gemzar
- Spectrum Pharma receives FDA approval for Zevalin
- FDA approves generic Casodex
- GlaxoSmithKline receives FDA approval for advanced renal cell carcinoma treatment
